Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Panacea Biotec's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹92 Mil. Panacea Biotec's average total tangible assets for the quarter that ended in Jun. 2026 was ₹12,113 Mil. Therefore, Panacea Biotec's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 0.76%.
The historical rank and industry rank for Panacea Biotec's Return-on-Tangible-Asset or its related term are showing as below:
BOM:531349'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -14.22 Med: -1.45 Max: 74.18
Current: -0.58
During the past 13 years, Panacea Biotec's highest Return-on-Tangible-Asset was 74.18%. The lowest was -14.22%. And the median was -1.45%.
BOM:531349's Return-on-Tangible-Asset is ranked better than 79.04% of 1412
companies
in the Biotechnology industry
Industry Median: -35.545
vs BOM:531349: -0.58
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Panacea Biotec Return-on-Tangible-Asset Related Terms
Panacea Biotec Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Panacea Biotec's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.76% mean?
Panacea Biotec (BOM:531349) has a Return-on-Tangible-Asset of 0.76% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Panacea Biotec and its competitors. According to the industry distribution chart, Panacea Biotec ranks #296 out of 1412 companies in the Biotechnology industry, placing it in the top 21%.
Is Panacea Biotec's Return-on-Tangible-Asset too high?
Panacea Biotec's current Return-on-Tangible-Asset is 0.76%. Based on the distribution chart, Panacea Biotec ranks #296 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Panacea Biotec has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #296 out of 1412 companies for Return-on-Tangible-Asset. This places Panacea Biotec in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current Return-on-Tangible-Asset is 0.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹404.96, compared to a current price of ₹382.00 — trading 5.7% below its estimated fair value. The current Return-on-Tangible-Asset is 0.76%. Panacea Biotec's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Return-on-Tangible-Asset is 0.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued.
The current stock price of ₹382.00 is trading 5.7% below its estimated GF Value™ of ₹404.96.
GuruFocus considers Panacea Biotec to be Fairly Valued.
Key valuation signals for BOM:531349:
Return-on-Tangible-Asset: 0.76%
GF Value™: ₹404.96 vs. price of ₹382.00 (5.7% below fair value)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
60GF Score
Get the complete analysis for BOM:531349
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
